In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and commercialise zorevunersen to treat Dravet syndrome ...

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...

Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a ...

The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...

Generally, a “Strong Buy” rating on Wall Street indicates that analysts believe the stock will appreciate and outperform the ...

--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the development and commercialization of zorevunersen, a potential ...

Discover Stoke Therapeutics' innovative RNA-based treatments like zorevunersen for Dravet syndrome, with a promising pipeline ...

Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...